These days, it's good to have your own money to bank on when you're growing a biotech company. It's also extraordinarily rare. The following 15 venture round qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association.
Most biotech analysts have been concentrating heavily on the weakened flow of venture dollars into the industry. But if you look at the licensing side of the business, you'll also find some solid reasons for concern.
Japan's Astellas will pay up to $130 million to license a vaccine to prevent cytomegalovirus (CMV) reactivation in transplant recipients. The disease is typically dormant in those who are healthy but
After hinting for some time that it's been shopping for a mid-stage product, Acorda this morning unveiled a $35 million licensing pact with Medtronic for a new therapy to treat neurological trauma
Sanofi chief and Genzyme conqueror Christopher Viehbacher put it this way: "You have to decide where you are strong in research and development and where you need partners,'' reports the Boston
Rockville, MD-based Sequella has completed a round of high-fives with leaders of the region's biotech community after inking a licensing pact covering Russia and surrounding states for its mid-stage
Canada's Aeterna Zentaris will pocket $8.3 million upfront from Yakult Honsha, which is licensing the Japanese rights to Aeterna's lead cancer drug, perifosine. Aeterna is also in line for up to
Seattle vaccine upstart Immune Design scored a $212 million licensing deal and some important industry cred with its new pact giving MedImmune the right to use its adjuvant in new vaccines. The deal
Last summer, Exelixis was forced to endure some harsh criticism after Bristol-Myers Squibb opted out of its closely-watched pact for the cancer drug XL184. And with CEO George Scangos leaving days
Irving, TX-based Reata Pharmaceuticals snared a treasure trove of $450 million in upfront and near-term cash from Abbott Labs in exchange for the ex-U.S. licensing rights to the mid-stage chronic